Review Article
[Retracted] Noscapine, an Emerging Medication for Different Diseases: A Mechanistic Review
Table 1
Evaluation of the effect of noscapine on cancer cells along with other first-line drugs.
| Noscapine | Anticancer drug | Type of cancer | Growth inhibition (%) | In vivo or in vitro | Ref. |
| 150–550 mg/kg/day | Doxorubicin (1.5 mg/kg) | Triple negative breast cancer (TNBC) | 39.4%–82.9% synergistic interaction between noscapine and doxorubicin | In vitro MDA-mb-231 and MDA-mb-468 cells | [36] | 300 mg/kg/day | Gemcitabine (30 mg/kg) | Non-small-cell lung cancer (NSCLC) | 82.9 ± 4.5 synergistic interaction between noscapine and gemcitabine | In vitro H460 tumors | [32] | 225 mg/kg twice per day | TMZ (5 mg/kg) | Glioblastoma multiforme TMZ-resistant | Noscapine increased survival in the orthotopic in vivo xenograft model of TMZ-resistant glioma. | In vitro U251 and A172 cells | [30] | 100 mg/kg/day | Docetaxel (0.4 μM) | Triple negative breast cancer | 30% increase in number of late apoptotic cells, synergistic interaction | In vitro MDA-mb-231 cells | [50] |
|
|